13,217 research outputs found
Sandy Freedman Oral History Interview
No full textFormer Tampa Mayor Sandy Freedman, discusses her life in politics in Tampa, Florida. She begins the interview with a brief discussion of her childhood and how she came to the Tampa Bay area. She also discusses her tenure on the Tampa City Council as a council member and later as chairman of the council. Ms. Freedman discusses her time as acting mayor and mayor of the city of Tampa from 1986 to1995. She also discusses city programs that were significant to her as mayor: Tampa Neighborhood Cleanup, the Growth Management Act of 1985 (neighborhood element), the Community Reinvestment Act (implemented on a local level), Tampa Heights building and redevelopment project, the sister-city program, and the building of the Tampa Convention Center. The interview ends with Ms. Freedman reflecting on her time as mayor and what she would have done differently
Mesenchymal stem cells as treatment for MS - progress to date.
No full textThe unmet need for therapies capable of repairing the central nervous system (CNS) damage occurring in many diseases including multiple sclerosis (MS) has sparked the interest of the neurological community for stem cell-based therapies. An exhaustive amount of preclinical data has shown that the intravenous administration of mesenchymal stem cells (MSC), a subset of progenitor cells isolated from many mesodermal tissues, effectively ameliorates experimental autoimmune encephalomyelitis (EAE), a model of MS, through the release of anti-inflammatory and neuroprotective molecules. Based on these results, several small pilot clinical trials in subjects with advanced MS have demonstrated that MSC administration is safe and provided an early signal of clinical effectiveness. The current aim of clinicians and scientists interested in the development of MSC-based strategies for the treatment of MS is to have the ultimate demonstration in large clinical trials that MSC can inhibit CNS inflammation and foster tissue repair as realized clinically, with functional recovery, or visualized by magnetic resonance imaging (MRI)
MSJ881761_supplementary_appendix – Supplemental material for Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
No full textSupplemental material, MSJ881761_supplementary_appendix for Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study by Robert T Naismith, Jerry S Wolinsky, Annette Wundes, Christopher LaGanke, Douglas L Arnold, Dragana Obradovic, Mark S Freedman, Mark Gudesblatt, Tjalf Ziemssen, Boris Kandinov, Ilda Bidollari, Maria Lopez-Bresnahan, Narinder Nangia, David Rezendes, Lili Yang, Hailu Chen, Shifang Liu, Jerome Hanna, Catherine Miller and Richard Leigh-Pemberton in Multiple Sclerosis Journal</p
Ms. Courtney Chartier, RWWL AUC, August 2011
No full textThis video is a conversation with Ms. Courtney Chartier. Ms. Chartier talks about her work on the "New Georgia Encyclopedia" and "Online Voter Education Project." Andrea Jackson, AUC Woodruff Library, is the interviewer
Ms. Neely Terrell, RWWL AUC, March 2012
No full textThis video is a conversation with Ms. Neely Terrell. Ms. Terrell talks about her book, "Super Singles Activate". Anthony Kinsey and Jahnesta Horney, AUC Woodruff Library, are the interviewers
Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
No full textBackground:Alemtuzumab is administered as two annual courses for relapsing-remitting multiple sclerosis (MS). Patients may relapse before completing the two-course regimen. Objective: The objective was to evaluate 6-year outcomes in patients who relapsed between alemtuzumab Courses 1 and 2 (early relapsers). Methods:Post hoc analysis of patients from the Comparison of Alemtuzumab and Rebif (R) Efficacy in Multiple Sclerosis (CARE-MS) studies who enrolled in the extension. Results:Early relapsers (CARE-MS I: 15%; CARE-MS II: 24%) had more relapses in 1-2 years pre-alemtuzumab and higher mean baseline Expanded Disability Status Scale score than patients without relapse. Their annualized relapse rate declined from Year 1 (CARE-MS I: 1.3; CARE-MS II: 1.2) to Year 2 following Course 2 (0.3; 0.5) and remained low thereafter. Over 6 years, 60% remained free of 6-month confirmed disability worsening; 24% (CARE-MS I) and 34% (CARE-MS II) achieved 6-month confirmed disability improvement. During Year 6, 69% (CARE-MS I) and 68% (CARE-MS II) were free of magnetic resonance imaging (MRI) disease activity. Median percent yearly brain volume loss (Year 1: -0.67% (CARE-MS I); -0.47% (CARE-MS II)) declined after Course 2 (Year 6: -0.24%; -0.13%). Conclusion: Early relapsers' outcomes improved after completing the second alemtuzumab course. These findings support administering the approved two-course regimen to maximize clinical benefit. ClinicalTrials.gov registration numbers:CARE-MS I, II, extension: NCT00530348, NCT00548405, NCT00930553.The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The CARE-MS I, CARE-MS II, and CAMMS03409 studies were funded by Sanofi and Bayer HealthCare Pharmaceuticals. Only Sanofi contributed to the conduct of the studies; collection, management, analysis, and interpretation of the data; review of the manuscript. Apart from the Sanofi employees listed as authors, the funders had no role in preparation, approval, and decision to submit the manuscript for publication.Van Wijmeersch, B (reprint author), Hasselt Univ, Fac Med & Life Sci, Campus Hasselt,Martelarenlaan 42, B-3500 Hasselt, Belgium.
[email protected]
Ms. Felesha Love, Spelman College, January 2016
No full textThis video is a conversation with Felesha Love. Ms. Love talks about her book, "Brave Leap to Freedom: Integrating Mind, Body, and Spirit to Cultivate Healthy Relationships". Jordan Moore, AUC Woodruff Library, is the interviewer
MSJ-19-0334.R2_Supplemental_Figure_1 – Supplemental material for Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
No full textSupplemental material, MSJ-19-0334.R2_Supplemental_Figure_1 for Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study by Robert T Naismith, Jerry S Wolinsky, Annette Wundes, Christopher LaGanke, Douglas L Arnold, Dragana Obradovic, Mark S Freedman, Mark Gudesblatt, Tjalf Ziemssen, Boris Kandinov, Ilda Bidollari, Maria Lopez-Bresnahan, Narinder Nangia, David Rezendes, Lili Yang, Hailu Chen, Shifang Liu, Jerome Hanna, Catherine Miller and Richard Leigh-Pemberton in Multiple Sclerosis Journal</p
MSJ-19-0334.R2_Supplemental_Figure_2 – Supplemental material for Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
No full textSupplemental material, MSJ-19-0334.R2_Supplemental_Figure_2 for Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study by Robert T Naismith, Jerry S Wolinsky, Annette Wundes, Christopher LaGanke, Douglas L Arnold, Dragana Obradovic, Mark S Freedman, Mark Gudesblatt, Tjalf Ziemssen, Boris Kandinov, Ilda Bidollari, Maria Lopez-Bresnahan, Narinder Nangia, David Rezendes, Lili Yang, Hailu Chen, Shifang Liu, Jerome Hanna, Catherine Miller and Richard Leigh-Pemberton in Multiple Sclerosis Journal</p
sj-pdf-2-msj-10.1177_13524585231205708 – Supplemental material for Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study
No full textSupplemental material, sj-pdf-2-msj-10.1177_13524585231205708 for Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study by Barry A Singer, Douglas L Arnold, Jelena Drulovic, Mark S Freedman, Ralf Gold, Mark Gudesblatt, Elzbieta Jasinska, Christopher C LaGanke, Robert T Naismith, Donald Negroski, Jiwon Oh, Miguel Angel Hernandez Perez, Krzysztof Selmaj, Florian Then Bergh, Annette Wundes, Tjalf Ziemssen, Wanda Castro-Borrero, Hailu Chen, Seth Levin, Matthew Scaramozza, Sai L Shankar, Ting Wang and Sibyl Wray in Multiple Sclerosis Journal</p
- …
